Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Nicole Mcneer"'
Autor:
Jeffrey Rubnitz, Ghayas C. Issa, Eytan M. Stein, Neerav Shukla, Wendy Stock, Andrius Žučenka, Sajad Khazal, Nandita Khera, Elliot Stieglitz, Jeremy Rubinstein, Galit Rosen, Rachel Ghiraldi, Huy Van Nguyen, Nicole Mcneer, C. Michel Zwaan
Publikováno v:
HemaSphere, Vol 7, p e221187f (2023)
Externí odkaz:
https://doaj.org/article/c2daa4c9e27a49ec8d84cb363b109f0b
Autor:
Ghayas C. Issa, Branko Cuglievan, Eytan Stein, Martha L. Arellano, Andrius Žucenka, Nandita Khera, Richard M. Stone, Michael J. Thirman, John F. DiPersio, Nicole Karras, Yu Gu, Rebecca G. Bagley, Galit Rosen, David Tamang, Kimberly Dishman, Sushama Scalera, Michael L. Meyers, Kate Madigan, Nicole McNeer, Ibrahim Aldoss
Publikováno v:
Blood. 140:914-916
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8de19932f8a29ddba13169e64695a07
https://doi.org/10.1182/blood-2022-164600
https://doi.org/10.1182/blood-2022-164600
Autor:
Marina Konopleva, Nitin Jain, Courtney L Andersen, Natalia Couto Francisco, Nairouz Elgeioushi, Rosalind Hobson, Martin Scott, John Stone, Shringi Sharma, Pablo Morentin Gutierrez, Raoul Tibes, Barry Davies, Thomas Winkler, Giulia Fabbri, Fathima Zumla Cader, Nicole McNeer
Publikováno v:
Blood. 138:2353-2353
Introduction: While BCL2 inhibition benefits many patients with acute myeloid leukemia (AML), resistance often occurs due to upregulation of other anti-apoptotic proteins such as MCL and BCLxL. Dual BCL2/xL inhibition with AZD4320 has potential for b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4f122dbd24f4468561aea8dda4056a9
https://doi.org/10.1182/blood-2021-147482
https://doi.org/10.1182/blood-2021-147482
Autor:
Nicole McNeer, John Philip, Heather Geiger, Rhonda E. Ries, Vincent-Philippe Lavallee, Michael Walsh, Minita Shah, Kanika Arora, Anne-Katrin Emde, Nicolas Robine, Todd A. Alonzo, E. Anders Kolb, Alan S. Gamis, Malcom Smith, Daniela Se Gerhard, Jaime Guidry-Auvil, Soheil Meshinchi, Alex Kentsis
Publikováno v:
Cancer Research. 79:2870-2870
Survival for children with acute myeloid leukemia (AML) remains low, with a primary induction remission failure rate of 10-15%. Although some mutations have been identified that are associated with increased relapse risk, the genomic landscape of ped
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::67d13a4e073ef1cd2903f5268b686006
https://doi.org/10.1158/1538-7445.am2019-2870
https://doi.org/10.1158/1538-7445.am2019-2870